Purpose Pharma
purposepharma.com
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Stockholm, July 31, 2025 – Purpose Pharma International AB today announced that the European Commission (EC) has granted ATTROGY® (diflunisal) marketing authorization for the treatment of hereditary transthyretin-mediated (hATTR or ATTRv) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
News
Purpose Pharma launches ATTROGY (diflunisal) for the treatment of hereditary transthyretin-mediated amyloidosis in Germany
Stockholm, November 17, 2025 - Purpose Pharma International AB today announced that ATTROGY (diflunisal) is now available in Germany for the treatment of hereditary transthyretin-mediated (hATTR or ATTRv) amyloidosis in adult patients with stage 1 or stag
Read more
Report
Purpose Pharma receives European Commission approval of ATTROGY (diflunisal) for the treatment of hereditary transthyretin-mediated amyloidosis
Stockholm, July 31, 2025 - Purpose Pharma International AB today announced that the European Commission (EC) has granted ATTROGY (diflunisal) marketing authorization for the treatment of hereditary transthyretin-mediated (hATTR or ATTRv) amyloidosis in ad
Read more
Report
Purpose Pharma receives positive CHMP opinion for Attrogy (diflunisal) for the treatment of hereditary transthyretin-mediated amyloidosis
Stockholm, April 28, 2025 - Purpose Pharma International AB today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Attrogy (diflunisal) for the treatment of
Read more
Report
Eir Ventures Invests in Purpose Pharma
Purpose Pharma International AB is pleased to announce that Eir Ventures has invested in an extension of the Series A financing completed in 2023.
Read more
Report
Industrifonden invests in the rare disease company Purpose Pharma
Stockholm, October 3, 2023 - Industrifonden has made a strategic investment in Purpose Pharma International AB, a pharmaceutical company focusing on specialty products for rare diseases for patient groups with limited alternatives. Purpose Pharma is led b
Read more
Report